|
Quotes & Info
|
| REGN > SEC Filings for REGN > Form 8-K on 20-Nov-2008 | All Recent SEC Filings |
20-Nov-2008
Change in Directors or Principal Officers
(e) Amendment and Restatement of Change in Control Severance Plan. On
November 14, 2008, the Compensation Committee of the Board of Directors of
Regeneron Pharmaceuticals, Inc. (the "Company") approved and adopted an
amendment and restatement of the Regeneron Pharmaceuticals, Inc. Change in
Control Severance Plan that was originally approved and adopted by the Board of
Directors on January 20, 2006. The purpose of the amendment and restatement was
to bring the Regeneron Pharmaceuticals, Inc. Change of Control Severance Plan
(as amended and restated, the "Plan") into compliance with Section 409A of the
Internal Revenue Code of 1986, as amended, and the regulations and other
guidance promulgated thereunder ("Section 409A"), which generally applies to
non-qualified deferred compensation arrangements and which can apply to
severance benefits.
The definition of "Good Reason" as set forth in the Plan was amended to more
closely conform to the definition set forth in Section 409A. In addition, the
Plan was amended to delete the ability of the Company to pay cash in lieu of a
participant's benefit continuation entitlement. Other technical amendments were
made to the Plan in order to bring the Plan into compliance with Section 409A.
Amendment and Restatement of Schleifer Employment Agreement. On November 14,
2008, the Compensation Committee of the Board of Directors of the Company
approved and entered into an amended and restated employment agreement with
Dr. Leonard Schleifer, the President and Chief Executive Officer of the Company
(the "Employment Agreement"), which amended and restated the Company's
December 20, 2002 employment agreement with Dr. Schleifer. The purpose of the
amendment and restatement was to bring the Employment Agreement into compliance
with Section 409A.
The Employment Agreement effects technical amendments to Dr. Schleifer's
December 20, 2002 employment agreement to bring the Employment Agreement into
compliance with Section 409A. The Employment Agreement now provides that
severance payments are always to be made in a lump sum rather than over time. If
Section 409A requires it, then any severance payments otherwise payable under
the Employment Agreement during the six month period immediately following the
termination of Dr. Schleifer's employment will be delayed and paid in a lump sum
as soon as practicable following the expiration of such six month period. The
Employment Agreement also now does not permit Dr. Schleifer to carry-over
certain unused reimbursement rights from year-to-year. The Company has agreed to
indemnify Dr. Schleifer in the event that payments under the Employment
Agreement are in violation of Section 409A.
|
|